Ironwood Pharmaceuticals is trading 5.19% up at $4.39, primarily amid a broader biotech-sector rally and improved risk appetite following the Federal Reserve decision.
- Biotechnology is up 2.55%.
- No new company-specific announcement was identified on September 17, 2026; the latest official release was the September 3 Wells Fargo conference participation notice.
- Recent Wells Fargo commentary on stronger LINZESS pricing and apraglutide remains supportive background, but is not new today.